Hypnomidate (Etomidate)

Etomidate acts by enhancing the activity of the GABA_A receptor, the main inhibitory neurotransmitter system in the brain. This potentiation increases chloride ion flow into neurons, hyperpolarizing them and producing a swift and profound reduction in central nervous system activity, leading to hypnosis and sedation.

The dose of Hypnomidate is determined by the prescribing clinician based on the patient’s age, weight, clinical condition, and the intended procedure. Dosage regimens are individualized, and the prescriber will calculate the appropriate amount and rate of intravenous administration.

The pregnancy category for etomidate is listed as unknown, and there is limited data on its use during lactation. Consequently, the drug should be used only if the potential benefit justifies any possible risk to the fetus or infant, and clinicians should exercise caution.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity of Hypnomidate. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Compared with agents such as propofol, etomidate (Hypnomidate) offers hemodynamic stability with less impact on blood pressure, making it useful in patients at risk of hypotension. However, it may cause adrenal suppression and myoclonus, whereas propofol is associated with more pronounced cardiovascular depression but fewer endocrine effects.

Hypnomidate should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. The container should remain sealed until use, and any unused portion should be discarded according to local regulations after the recommended shelf‑life.

Hypnomidate is supplied as an injectable solution for intravenous administration. It is typically given as a rapid bolus injection over 30–60 seconds, followed by an infusion if maintenance of anesthesia is required. Administration must be performed by qualified healthcare professionals in a controlled setting.

The most serious risks include adrenal suppression, which can impair cortisol production, severe hypotension or cardiovascular collapse, and rare but life‑threatening allergic reactions such as anaphylaxis. Continuous monitoring of vital signs and endocrine function is essential during and after administration.

Hypnomidate is contraindicated in patients with known hypersensitivity to etomidate or any of its excipients. Caution is advised for individuals with severe adrenal insufficiency, uncontrolled sepsis, or those who have experienced adverse reactions to similar intravenous anesthetics.